[1] |
Da RIM, Gasparotto AS, Lazzaretti RK, et al.Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort[J]. Pharmacogenet Genomics, 2015, 25(11): 541-547.
|
[2] |
Lucas S, Nelson AM.HIV and the spectrum of human disease[J].J Pathol, 2015, 235(2):229-241.
|
[3] |
Spaulding A, Rutherford GW, Siegfried N.Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals[J].Cochrane Database Syst Rev, 2010,17(3):385-403.
|
[4] |
Verhelst D, Monge M, Meynard JL, et al.Fanconi syndrome and renal failure induced by tenofovir: A first case report[J].Am J Kidney Dis, 2002,40(6):1331-1333.
|
[5] |
Brennan A,Evans D, Maskew M, et al.Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir[J].Aids,2011,25(13):1603-1609.
|
[6] |
Seedat F, Martinson NA, Motlhaoleng K,et al.Acute kidney injury,risk factors and prognosis in hospitalized HIV-infected adults in South Africa,compared by tenofovir exposure[J].Aids Res Hum Retrovir,2017,33(1):33-40.
|
[7] |
Zhao Y, Zhang M, Shi CX,et al.Renal function in Chinese HIV-positive individuals following initiation of antiretroviral therapy[J].PLoS One,2015,10(8):e0135462.
|
[8] |
中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册[M].3版. 北京:人民卫生出版社,2012:41-44.
|
[9] |
中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册[M].4版. 北京:人民卫生出版社,2016:43-45.
|
[10] |
万学红,卢雪峰.诊断学[M].9版. 北京:人民卫生出版社,2018:341-342.
|
[11] |
陈灏珠,钟南山,陆再英.内科学[M].9版. 北京:人民卫生出版社,2018:459-460.
|
[12] |
Stevens PE, Levin A,Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11):825-830.
|
[13] |
Achhra AC, Nugent M, Mocroft A, et al.Chronic kidney disease and antiretroviral therapy in HIV-positive individuals:Recent developments[J].Curr Hiv/Aids Rep,2016,13(3):149-157.
|
[14] |
Clumeck N, Pozniak A, Raffi F, et al.European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults[J]. HIV Med,2008,9(2):65-71.
|
[15] |
李杰,林鹏,李艳,等.广东省高效抗逆转录病毒治疗艾滋病病毒感染者/患者免疫学和病毒学评价[J].华南预防医学,2015,41(2):113-116.
|
[16] |
Wu YS, Zhang WW, Ling XM, et al.Efficacy and safety of tenofovir and lamivudine in combination with efavirenz in patients co-infected with human immunodeficiency virus and hepatitis B virus in China[J]. Chin Med J,2016,129(3):304-308.
|
[17] |
曹丕,吴建军,苏斌,等.艾滋病患者更换二线抗病毒药物的治疗效果[J].中国热带医学,2018,18(4):387-390.
|
[18] |
Nishijima T, Kawasaki Y, Mutoh Y, et al.Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo[J]. Sci Rep,2017,7(1):14565.
|
[19] |
覃善芳,江建宁,黄维, 等.替诺福韦对初治人类免疫缺陷病毒感染者和HIV/AIDS肾功能的影响[J].中华传染病杂志,2018,36(2):78-82.
|
[20] |
Bregigeon S, Solas C, Faucher O, et al.Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration[J]. Antivir Ther,2017,22(6):529-533.
|
[21] |
Jung WJ,Jang JY,Park WY, et al.Effect of tenofovir on renal function in patients with chronic hepatitis B[J].Medicine (Baltimore),2018,97(7):e9756.
|
[22] |
Ryom L,Mocroft A,Kirk O,et al.Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function:the D:A:D study[J].J Infect Dis,2013,207(9):1359-1369.
|
[23] |
Pujari SN, Smith C, Makane A, et al.Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: A comparative cohort analysis between Western India and United Kingdom[J].BMC Infect Dis,2014,14(1):173.
|
[24] |
Hentzien M,Drame M,Allavena C,et al.Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era-Role of chronic renal disease[J].J Nutr Health Aging,2016,20(4):408-414.
|
[25] |
Brito RM,Nguyen DT,Johnson JR,et al.Chronic kidney disease in patients infected with human immunodeficiency virus (HIV) in an urban cohort[J].PLoS One, 2019, 14(4):e0215575.
|
[26] |
Santiago P,Grinsztejn B,Friedman RK,et al.Screening for decreased glomerular filtration rate and associated risk factors in a cohort of HIV-infected patients in a middle-income country[J].PLoS One,2014,9(4):e93748.
|
[27] |
Wong C, Gange SJ, Buchacz K, et al.First Occurrence of diabetes,chronic kidney disease,and hypertension among North American HIV-infected adults,2000-2013[J]. Clin Infect Dis,2017,64(4):459-467.
|
[28] |
Ding Y,Duan S,Ye R, et al.Effects of aging,baseline renal function and stage of HIV infection on post-treatment changes in renal function among HIV-infected patients:A retrospective cohort study[J].HIV Med,2019, 20(9):591-600.
|
[29] |
Touzard RF, Smeaton LM, Campbell TB,et al.Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting:A focused safety analysis of ACTG PEARLS (A5175)[J]. HIV Clin Trials,2014,15(6):246-260.
|
[30] |
陈伟烈,何瑞英,雷华丽,等.HAART过程HIV/AIDS患者PBMC中HIV-1前病毒DNA的动态变化及其意义[J].分子诊断与治疗杂志,2018,10(6):390-394,416.
|